Overcoming drug resistance
Our laboratory studies the molecular mechanisms that drive intrinsic and acquired drug resistance to inhibitors of the tumor microenvironment, with a specific focus on treatments targeting the immune system and the process of angiogenesis (i.e, tumor blood vessels).
Meet the PI
Finding ways to improve immune and angiogenesis targeting therapy
Our research aims to exploit the unexpected side effects of cancer treatments that can drive resistance and impact spontaneous metastatic disease. Our long-term goal is pairing novel experimental therapeutics in clinically relevant preclinical models with ongoing patient trials to better predict the drug combinations that will work in patients.
New publication: Combining VEGFR-targeting TKIs with checkpoint inhibitors
Oral cancer drugs that target tumors by restricting new blood vessel growth, or angiogenesis, can also highjack senescence, a process related to cellular aging.
Prestigious research funding
Therapy-induced Secretomes as Drivers of Antiangiogenic Drug Resistance
- Award: Research Scholar Grant
- Source: American Cancer Society
- Goal: Therapy-induced secretomes as drivers of antiangiogenic drug resistance
Antiangiogenic therapy resistance in kidney metastasis
- Award: Career Development Award
- Source: U.S. Department of Defense
- Goal: Distinguishing Tumor- and Stromal-Mediated Mechanisms of Resistance and Rebound in Models of Metastatic Renal Cell Carcinoma
Faculty affiliations
Connect with the Ebos Lab
EmailX (Twitter)BlueSkyLinkedIn
Department of Cancer Genetics & Genomics
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263